Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

In the ESCAPE-TRD study, Spravato outperformed quetiapine on the main endpoint of achieving remission at eight weeks, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with rates ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of sufficient efficacy, the drug and medical device maker said on Thursday.

Jessica Mendoza: Sean has what's called treatment-resistant depression, and a few years ago he found out about a new kind of treatment that might help him. It's called Spravato, and it's made by ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" ...

Spravato (esketamine) is prescribed for adults to treat: major depressive disorder (MDD), also called depression, with suicidal thoughts or actions treatment-resistant depression For MDD ...

"With Limitless Guided Visualizations, we're able to offer our patients an added layer of support that complements their ...

The expansion is effective immediately, nearly one year after NeuroStar ® Advanced Therapy received FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. In the ...